Healthcare and life sciences

Rymarz Zdort Maruta

Rymarz Zdort Maruta regularly acts for a lucrative, global client base, which notably includes Takeda Pharmaceutical Company Limited, Eli Lilly Poland Sp. z o.o., and Bausch + Lomb. Michał Czarnuch has deep knowledge of cases involving corruption allegations, healthcare service financing, and the restructuring of healthcare providers. Tomasz Kaczyński is noted for his longstanding experience in product registration, advertising, and distribution issues, in addition to the law governing dietary supplements and franchising. Marcin Pieklak is a key contact for pharmaceutical companies seeking advice on reimbursement procedures.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘Not only excellent knowledge of pharmaceutical law, medical device law and food law, but also vast knowledge of the practical aspects of running a business in these areas.’
‘Tomasz Kaczyński is an excellent and very experienced lawyer with a great understanding of customer needs and attitude.’
‘Michał Czarnuch stands out for his intelligence and reliability in operational work. Working with him, I am confident that tasks will be completed, and I will receive a high-quality final product. If I need anything additional, he is capable of making adjustments and taking on extra work on his own initiative.’

Key clients

Celon Pharma S.A.
Exeltis Poland Sp. z o.o.
Benefit Systems S.A.
Ravimed Sp. z o.o.
Polska Izba Ubezpieczeń
Hemolens Diagnostics Sp. z o.o.
Bausch + Lomb
Coloplast AG
Eli Lilly Poland Sp. z o.o.
Takeda Pharmaceutical Company Limited

Work highlights

Advised Exeltis Poland Sp. z o.o. on the establishment of cooperation schemes with telemedicine clinics, the launch of a diagnostic test classified as a medical decice, and reimbursement procedures for core products.
Advised Coloplast AG on the financing of medical devices by the National Health Fund to one of the manufacturers of special purpose dressings.
Advised Celon Pharma S.A. on optimising the company's distribution structure, managing multinational distribution, and establishing co-promotion agreements and innovation funds.